Do you want to read an article? Please log in or register.
Elexacaftor/tezacaftor/ivacaftor improves CFTR function to near-normal levels in children with cystic fibrosis
Pulmonary Fibrosis
Related content
RECOMMENDED
Pulmonary Fibrosis
Improvement in functional exercise performance and quadriceps muscle strength after two years treatment with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: A prospective observational study
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Cyst Fibros
Aubriot AS, Song C, Gonçalvès C, Santelé L, Berardis S, Goubau C, Reychler G, Penelle M, Gohy S
doi: 10.1016/j.jcf.2026.07.003
RECOMMENDED
Pulmonary Fibrosis
Impact of Elexacaftor-Tezacaftor-Ivacaftor on fungal colonisation in children and adolescents with cystic fibrosis
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Cyst Fibros
Sitterlé E, Bonnel AS, Roussey-Bihouee T, Blondé A, Ribault M, Wizla N, Bresson C, Persat F, Maubon D, Leroy J, Hassani F, Benhala L, Mounier M, Znaidi S, Ferroni A, Bougnoux ME, Sermet-Gaudelus I, Mycologist and Modul-CF groups
doi: 10.1016/j.jcf.2026.02.012
Pulmonary Fibrosis
Real-world Efficacy, Safety and Heterogenicity of Efficacy of Elexacaftor-Tezacaftor-Ivacaftor in Younger Children (6-11 Years Old) with Cystic Fibrosis
Respir Med
Sheikh S, Holtzlander M, Eisner M, Gushue C, Palacios S, Mull E, Imran S, Kotha K, McCoy KS
doi: 10.1016/j.rmed.2026.109063
RECOMMENDED
Pulmonary Fibrosis
Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in adolescents and adults with cystic fibrosis and F508del-gating and F508del-residual function genotypes: Results from an open-label extension study
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Ann Am Thorac Soc
Chmiel JF, McBennett K, Quon BS, Colombo C, De Wachter E, Fajac I, Mondejar-Lopez P, Polineni D, Robinson P, Sutharsan S, Mall MA, McKone EF, Ramsey B, Taylor-Cousar JL, Tullis E, Suresh NE, Zhang Y, Sosnay P, Jennings M, Barry PJ, 445-110 study group
doi: 10.1093/annalsats/aaoag053
Pulmonary Fibrosis
Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children ≥2 years with cystic fibrosis: 96-week interim results from a phase 3 open-label extension study
J Cyst Fibros
Goralski JL, Daines C, Pittman JE, Rayment JH, Robinson P, Thursfield R, Stehling F, Ratjen F, Ahluwalia N, Shi P, Lu M, Weinstock TG, Mall MA, VX20-445-112 Study Group
doi: 10.1016/j.jcf.2026.05.014
RECOMMENDED
Pulmonary FibrosisBronchi
Effect of elexacaftor-tezacaftor-ivacaftor on bronchial dilatations in adolescents with cystic fibrosis: a multicentre prospective observational study
★ 3
Recommended by
Dr. med. Martin Frey, Faculty Member
Lancet Respir Med
Sermet-Gaudelus I, Letierce A, Berteloot L, Bonnel AS, Chen Y, Makani P, Kelly-Aubert M, Kanoun F, Penalva L, Bouleghem N, Bihouee T, Bui S, Corvol H, Houdouin V, Mittaine M, Tatopoulos A, Weiss L, Wizla N, Kapel N, Bessou A, Tiddens HAWM, Caudri D, Reix P, Marguet C, MODUL-CF study group
doi: 10.1016/S2213-2600(25)00248-6
Pulmonary HypertensionFurther Publications
Assessment of efficacy and tolerability of elexacaftor-tezacaftor-ivacaftor in an observational cohort study of "aged" people with cystic fibrosis
Ther Adv Respir Dis
Blankenship S, Flueckiger BV, Caleb G, Bailey J, Baker E, Garcia B, Krick S
doi: 10.1177/17534666251410246
Pulmonary Fibrosis
Pregnancy-related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis
Br J Clin Pharmacol
Magnas P, Bouazza N, Foissac F, Urien S, Froelicher-Bournaud L, Lui G, Guillemart V, Carlier N, Da Silva J, Fesenbeckh J, Kanaan R, Honoré I, Martin C, Treluyer JM, Tsatsaris V, Burgel PR, Benaboud S
doi: 10.1002/bcp.70620
Pulmonary Fibrosis
Real-World Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis: A 24-Month Italian National Registry Study
J Clin Med
Salvatore D, Campagna G, Padoan R, Pepe A, Amato A, Salvatore M
doi: 10.3390/jcm15072699